Ask AI
ProCE Banner Activity

Essential Thrombocythemia (ET) or Polycythemia Vera (PV) Treatment: A Global Patient–Provider Communication Checklist

PDF

Download this brief resource for your patients with essential thrombocythemia or polycythemia vera to help them understand their disease and potential treatments and ask informative questions during discussions with their HCP.

Released: April 15, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

Supported by an educational grant from Merck Sharp & Dohme LLC.

Merck Sharp & Dohme, LLC

Target Audience

This activity is intended for hematologists and other healthcare professionals caring for patients with essential thrombocythemia and polycythemia vera.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Identify underlying MPNs such as ET and PV in patients presenting with thrombotic events that are otherwise unexplained

  • Diagnose patients with ET and PV, including bone marrow biopsies and assessment of risk of thrombotic events

  • Determine prognoses for individual patients with ET and PV using prognostic scoring system and identification of immune biomarkers

  • Engage patients with ET and PV in shared-decision making to better align treatment with both best practices and patient preferences on risks and benefits

  • Prepare clinical practice to incorporate new second-line agents for ET and PV upon approval

Disclosure

Primary Author

Claire Harrison, MD, FRCP, FRCPath: consultant/advisor/speaker: AOP, Galecto, GSK, Inctye, Johnson & Johnson, Novartis, Syntara.

Jean-Jacques Kiladjian, MD, PhD: consultant/advisor/speaker: AbbVie, AOP, Bristol Myers Squibb, GSK, Novartis.